|Grant Number:||3R01CA093435-06S1 Interpret this number|
|Primary Investigator:||Goldie, Sue|
|Project Title:||Clinical & Cost Effectiveness of HPV Vaccination in the Us|
DESCRIPTION (provided by applicant): Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of HPV, promising new screening approaches using HPV DNA testing, and the recent licensure of the first prophylactic HPV vaccine targeting the two most common high-risk types of HPV, 16 and 18. We propose to refine our Cervical Cancer Screening Model to be capable of assessing the costs, benefits, and cost-effectiveness of primary prevention (vaccination), secondary prevention (screening), and strategies that combine both. Our specific aims are: (1) to refine a natural history model to function as an open population- based simulation model capable of forecasting incidence, mortality, and costs associated with different cervical cancer control strategies. This model will be calibrated to the United States population using the best available data, including observed patterns in HPV type-specific prevalence, invasive cancer, and temporal variation in factors such as sexual behavior and smoking; (2) to develop a dynamic transmission model of HPV 16 and 18 to estimate the population-level impact of a type-specific vaccination taking into account biological and host factors, vaccine properties, behavioral issues, and herd immunity. We will assess the incremental benefit of vaccinating boys in addition to girls under different scenarios; compare the costs and benefits of policies restricting vaccination to young girls not yet sexually active with policies extending vaccination to women in their late 20s; explore how uncertain assumptions about sexual mixing patterns affect results; and project temporal trends in type-specific HPV prevalence; (3) to assess the cost-effectiveness of alternative cervical cancer prevention strategies for a the general U.S. population as well as for subgroups that differ in their socioeconomic, demographic, and cervical cancer risk profile. We will explore how the cost-effectiveness of a combined screening and vaccination program could change over time, evaluate the effect of vaccination on the test performance of current HPV diagnostics; and assess how vaccine delivery (target age, upper age limit, coverage by age and risk group), vaccine characteristics, and programmatic features influence projected benefits and cost-effectiveness.
Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
Authors: Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ
Source: Br J Cancer, 2012 Apr 24;106(9), p. 1571-8.
EPub date: 2012 Mar 22.
Policy implications of adjusting randomized trial data for economic evaluations: a demonstration from the ASCUS-LSIL Triage Study.
Authors: Campos NG, Castle PE, Schiffman M, Kim JJ
Source: Med Decis Making, 2012 May-Jun;32(3), p. 400-27.
EPub date: 2011 Dec 6.
Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa.
Authors: Campos NG, Kim JJ, Castle PE, Ortendahl JD, O'Shea M, Diaz M, Goldie SJ
Source: Int J Cancer, 2012 Jun 1;130(11), p. 2672-84.
EPub date: 2011 Aug 24.
Persistence of concurrent infections with multiple human papillomavirus types: a population-based cohort study.
Authors: Campos NG, Rodriguez AC, Castle PE, Herrero R, Hildesheim A, Katki H, Kim JJ, Wacholder S, Morales J, Burk RD, Schiffman M
Source: J Infect Dis, 2011 Mar 15;203(6), p. 823-7.
EPub date: 2011 Jan 21.
Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests.
Authors: Price RA, Frank RG, Cleary PD, Goldie SJ
Source: Med Care, 2011 Feb;49(2), p. 132-8.
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis.
Authors: Kim JJ
Source: Lancet Infect Dis, 2010 Dec;10(12), p. 845-52.
EPub date: 2010 Nov 2.
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
Authors: Kim JJ, Ortendahl J, Goldie SJ
Source: Ann Intern Med, 2009 Oct 20;151(8), p. 538-45.
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.
Authors: Kim JJ, Goldie SJ
Source: BMJ, 2009 Oct 8;339, p. b3884.
EPub date: 2009 Oct 8.
Program spending to increase adherence: South African cervical cancer screening.
Authors: Goldhaber-Fiebert JD, Denny LA, De Souza M, Kuhn L, Goldie SJ
Source: PLoS One, 2009 May 28;4(5), p. e5691.
EPub date: 2009 May 28.
Health and economic implications of HPV vaccination in the United States.
Authors: Kim JJ, Goldie SJ
Source: N Engl J Med, 2008 Aug 21;359(8), p. 821-32.
The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.
Authors: Kim JJ, Andres-Beck B, Goldie SJ
Source: Br J Cancer, 2007 Nov 5;97(9), p. 1322-8.
EPub date: 2007 Oct 9.
Multiparameter calibration of a natural history model of cervical cancer.
Authors: Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ
Source: Am J Epidemiol, 2007 Jul 15;166(2), p. 137-50.
EPub date: 2007 May 25.
A public health approach to cervical cancer control: considerations of screening and vaccination strategies.
Authors: Goldie S
Source: Int J Gynaecol Obstet, 2006 Nov;94 Suppl 1, p. S95-105.
Packaging health services when resources are limited: the example of a cervical cancer screening visit.
Authors: Kim JJ, Salomon JA, Weinstein MC, Goldie SJ
Source: PLoS Med, 2006 Nov;3(11), p. e434.
Cost-effectiveness of cervical-cancer screening in five developing countries.
Authors: Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, Wright TC, Alliance for Cervical Cancer Prevention Cost Working Group
Source: N Engl J Med, 2005 Nov 17;353(20), p. 2158-68.
Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Authors: Kim JJ, Wright TC, Goldie SJ
Source: J Natl Cancer Inst, 2005 Jun 15;97(12), p. 888-95.
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Authors: Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E
Source: J Natl Cancer Inst, 2004 Apr 21;96(8), p. 604-15.
Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Authors: Goldie SJ, Kim JJ, Wright TC
Source: Obstet Gynecol, 2004 Apr;103(4), p. 619-31.
A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
Authors: Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E
Source: Int J Cancer, 2003 Oct 10;106(6), p. 896-904.